A citation-based method for searching scientific literature

Kaelen C Dunican, Nicole M Adams, Alicia R Desilets. Ann Pharmacother 2010
Times Cited: 19







List of co-cited articles
117 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.
Eric Ravussin, Steven R Smith, Julie A Mitchell, Reshma Shringarpure, Kevin Shan, Holly Maier, Joy E Koda, Christian Weyer. Obesity (Silver Spring) 2009
188
31

Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product.
G Christopoulos, K J Perry, M Morfis, N Tilakaratne, Y Gao, N J Fraser, M J Main, S M Foord, P M Sexton. Mol Pharmacol 1999
320
26

Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies.
Jonathan D Roth, Barbara L Roland, Rebecca L Cole, James L Trevaskis, Christian Weyer, Joy E Koda, Christen M Anderson, David G Parkes, Alain D Baron. Proc Natl Acad Sci U S A 2008
273
21

Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes.
Gina Ryan, Tim A Briscoe, Lynette Jobe. Drug Des Devel Ther 2009
44
21

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
W Philip T James, Ian D Caterson, Walmir Coutinho, Nick Finer, Luc F Van Gaal, Aldo P Maggioni, Christian Torp-Pedersen, Arya M Sharma, Gillian M Shepherd, Richard A Rode,[...]. N Engl J Med 2010
477
21


Central nervous system control of food intake.
M W Schwartz, S C Woods, D Porte, R J Seeley, D G Baskin. Nature 2000
15

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
M H Davidson, J Hauptman, M DiGirolamo, J P Foreyt, C H Halsted, D Heber, D C Heimburger, C P Lucas, D C Robbins, J Chung,[...]. JAMA 1999
529
15


Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults.
Ira Gantz, Ngozi Erondu, Madhuja Mallick, Bret Musser, Rajesh Krishna, Wesley K Tanaka, Karen Snyder, Cathy Stevens, Mark A Stroh, Haiyuan Zhu,[...]. J Clin Endocrinol Metab 2007
98
15

PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans.
Benjamin C T Field, Alison M Wren, Veronique Peters, Kevin C R Baynes, Niamh M Martin, Michael Patterson, Sara Alsaraf, Vian Amber, Katie Wynne, Mohammad A Ghatei,[...]. Diabetes 2010
73
15


Adjunct therapy for type 1 diabetes mellitus.
Harold E Lebovitz. Nat Rev Endocrinol 2010
32
15


Central and peripheral administration of amylin induces energy expenditure in anesthetized rats.
Toshimasa Osaka, Ayako Tsukamoto, Yu Koyama, Shuji Inoue. Peptides 2008
31
15



Meta-analysis: pharmacologic treatment of obesity.
Zhaoping Li, Margaret Maglione, Wenli Tu, Walter Mojica, David Arterburn, Lisa R Shugarman, Lara Hilton, Marika Suttorp, Vanessa Solomon, Paul G Shekelle,[...]. Ann Intern Med 2005
438
15


Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.
Arne Astrup, Sten Madsbad, Leif Breum, Thomas J Jensen, Jens Peter Kroustrup, Thomas Meinert Larsen. Lancet 2008
105
15

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
Arne Astrup, Stephan Rössner, Luc Van Gaal, Aila Rissanen, Leo Niskanen, Mazin Al Hakim, Jesper Madsen, Mads F Rasmussen, Michael E J Lean. Lancet 2009
563
15

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Frank L Greenway, Ken Fujioka, Raymond A Plodkowski, Sunder Mudaliar, Maria Guttadauria, Janelle Erickson, Dennis D Kim, Eduardo Dunayevich. Lancet 2010
391
15

The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men.
A Sjödin, C Gasteyger, A-Lh Nielsen, A Raben, J D Mikkelsen, J K S Jensen, D Meier, A Astrup. Int J Obes (Lond) 2010
28
15



Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity.
Steve R Smith, Louis J Aronne, Colleen M Burns, Nicole C Kesty, Amy E Halseth, Christian Weyer. Diabetes Care 2008
85
15

Mechanisms linking obesity to insulin resistance and type 2 diabetes.
Steven E Kahn, Rebecca L Hull, Kristina M Utzschneider. Nature 2006
15

Pramlintide and the treatment of diabetes: a review of the data since its introduction.
Lisa M Younk, Maia Mikeladze, Stephen N Davis. Expert Opin Pharmacother 2011
48
15

Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide.
C M Mack, P A Smith, J R Athanacio, K Xu, J K Wilson, J M Reynolds, C M Jodka, M G W Lu, D G Parkes. Diabetes Obes Metab 2011
25
15


Primer on pramlintide, an amylin analog.
Andrea N Traina, Michael P Kane. Diabetes Educ 2011
8
37


Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients.
J Jordan, F L Greenway, L A Leiter, Z Li, P Jacobson, K Murphy, J Hill, L Kler, R P Aftring. Clin Pharmacol Ther 2008
69
10

The role of amylin in the control of energy homeostasis.
Thomas A Lutz. Am J Physiol Regul Integr Comp Physiol 2010
87
10

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes.
Julio Rosenstock, Leslie J Klaff, Sherwyn Schwartz, Justin Northrup, John H Holcombe, Kenneth Wilhelm, Michael Trautmann. Diabetes Care 2010
135
10

Mechanisms of amylin/leptin synergy in rodent models.
Victoria F Turek, James L Trevaskis, Barry E Levin, Ambrose A Dunn-Meynell, Boman Irani, Guibao Gu, Carrie Wittmer, Peter S Griffin, Calvin Vu, David G Parkes,[...]. Endocrinology 2010
89
10

Leptin.
R S Ahima, J S Flier. Annu Rev Physiol 2000
10


A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity.
George A Bray, Priscilla Hollander, Samuel Klein, Robert Kushner, Brian Levy, Martin Fitchet, Barbara H Perry. Obes Res 2003
201
10

The role of gut hormones and the hypothalamus in appetite regulation.
Keisuke Suzuki, Katherine A Simpson, James S Minnion, Joyceline C Shillito, Stephen R Bloom. Endocr J 2010
138
10

Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents.
David Maahs, Daniela Gonzalez de Serna, Ronette L Kolotkin, Shawn Ralston, Jeffrey Sandate, Clifford Qualls, David S Schade. Endocr Pract 2006
81
10

Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial.
Katie Wynne, Adrian J Park, Caroline J Small, Michael Patterson, Sandra M Ellis, Kevin G Murphy, Alison M Wren, Gary S Frost, Karim Meeran, Mohammad A Ghatei,[...]. Diabetes 2005
243
10


The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.
M S Fineman, J E Koda, L Z Shen, S A Strobel, D G Maggs, C Weyer, O G Kolterman. Metabolism 2002
80
10

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease.
P Bongioanni, C Reali, V Sogos. Cochrane Database Syst Rev 2004
45
10


CNTF: a target therapeutic for obesity-related metabolic disease?
Vance B Matthews, Mark A Febbraio. J Mol Med (Berl) 2008
24
10

Obesity.
Susan Z Yanovski, Jack A Yanovski. N Engl J Med 2002
360
10

Serum immunoreactive-leptin concentrations in normal-weight and obese humans.
R V Considine, M K Sinha, M L Heiman, A Kriauciunas, T W Stephens, M R Nyce, J P Ohannesian, C C Marco, L J McKee, T L Bauer. N Engl J Med 1996
10



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.